Q-omics provides the consensus-scored LACTB profile across patient tissues and cancer cell-line models. LACTB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LACTB is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LACTB protein abundance shows 23,858 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KICH, and HNSC as cancer lineages where LACTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LACTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LACTB survival associations across molecular data types. LACTB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LACTB RNA expression–survival associations across cancer types. High LACTB expression shows unfavorable associations in KICH, LGG and PAAD, but favorable associations in SKCM, ACC and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LACTB RNA expression.
This table summarizes LACTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LACTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LACTB shows higher tumor expression in HNSC, STAD, KIRC, BLCA, LIHC and BRCA. The HNSC box plot shows higher LACTB RNA expression in tumor versus normal tissue (log2 FC = +1.526, t-test p < 0.001).
This table shows molecular features associated with LACTB in patient tissues and cancer cell lines. In patient samples, LACTB shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, LACTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
